Retroviral insertional mutagenesis in BXH2 mice commonly induces myeloid leukemias. One of the most frequently involved genes in experimental studies is Meis 1. In contrast to other genes in murine models, Meis 1 has not been affected by recurrent chromosomal translocations or point mutations in human leukemias. We found a constant downregulation of the Meis 1 gene mRNA in AML1-ETO acute myeloid leukemias and in those cases harboring in frame mutations in the bZIP domain of CEBPa. The absence of the Meis 1 mRNA was not caused by inactivating point mutations in the coding sequence. Promoter hypermethylation was present in more than half of the cases (9/14), including samples obtained from the widely employed Kasumi-1 cell line. Double treatment with 5-Aza-2 0 -deoxycytidine and trichostatin A of the Kasumi-1 cell line partially reverses Meis 1 inhibition. HoxA9 levels were also low. In a cell line model (U937 Tet AML1-ETO), AML1-ETO expression was not associated with Meis 1 suppression at 72 h. Nevertheless, Meis 1 repression is dependent on the AML1-ETO transcript levels in treated leukemic patients. Chimeric products that arise from chromosomal translocations may be associated with locus-specific epigenetic inactivation. It remains to be investigated when this methylation process is acquired and which are the basic mechanisms underlying these molecular events in AML1-ETO and CEBPa-mutated AML.
Introduction
Acute myeloid leukemia (AML) results from the acquisition of mutations in myeloid progenitors. Core-binding factors (CBF) are heterodimeric transcription factors that serve as regulators of normal myeloid lineage development. CBF are frequent targets of gene rearrangements and mutations in AML cases. The most common chromosomal translocations encountered in human AML involve AML1 and CBFb as a result of the t(8;21)(q22;q22) and inv(16)(p13;q22). 1 However, CBF mutations are not sufficient to cause AML, and additional mutations (receptor tyrosine-kinases, ras) seem to be required for the development of the full leukemic phenotype. 2 Meis 1 and Meis 2 are homeodomain genes which cooperate with Hoxa9 in AML experimental models. Hoxa9 is involved in chromosomal translocations in human leukemias and is one of the few molecules with an intrinsic ability to expand stem cells. Furthermore, both Hoxa9 and Meis 1 have been shown to be upregulated in leukemias with a very poor prognosis (leukemias with MLL rearrangements). [3] [4] [5] Although Meis 1 gene is very often involved in virally induced murine leukemia, [6] [7] [8] there are few data on its role in humans. Meis 1 gene was investigated in a consecutive series of de novo acute myeloid leukemias.
Material and methods

Patients
In total, 139 consecutive adult AML patients enrolled in the LAM99 protocol from the cooperative CETLAM group were included in the study. Cases were categorized into different groups according to the molecular lesions as follows: Group 1 (AML1-ETO, n ¼ 19), Group 2 (CBFb-MYH11, n ¼ 18), Group 3 (CEBPa mutated, n ¼ 6), Group 4 (AML1 mutated, n ¼ 4) and Group 5 (all other leukemia cases, n ¼ 92). Three normal bone marrow samples were used as calibrator samples. All cases were analyzed at diagnosis.
Cell lines included in this work were purchased from DSMZ and were: RAJI (Burkitt's lymphoma), Kasumi (human acute myeloid leukemia which carries a (8;21) translocation and involves AML1-ETO) and NB-4 (human acute promyelocytic leukemia with the t(15;17) and PML-RARA fusion gene).
RNA analysis
Total RNA was extracted from bone marrow samples quantified by spectrophotometry, and input amounts were optimized for retrotranscription. In all, 1 mg of RNA was retrotranscribed in a total reaction volume of 20 ml containing Cl 2 Mg 5 mM, 10 Â buffer, DTT 10 mM, dNTP's 10 mM each, random hexamers 15 mM, RNAsin 20 units and 200 units of RT enzyme. Samples were incubated for 10 min at 201C, 45 min at 421C and 3 min at 991C, followed by 10 min at 41C.
Gene expression
Gene expression of Meis 1, Hox A9 and Meis 2 was monitored by quantitative real-time RT-PCR using the Assays on Demand s on an ABI PRISM 7700 (Applied Biosystems, Foster City, CA, USA) and calculated employing the DDC T method (PE Applied Biosystems User Bulletin #2; ABI PRISM 7700 Sequence Detection System, 1997). PCR reactions were set up in MicroAmp optical 96-well reaction plates. After 2 min at 501C, the amplification was carried out by 40 cycles at 951C for 15 s and 651C for 60 s in the ABIPRISM 7700 Sequence Detector System. Each sample was analyzed in duplicate and normalized to the Abl levels, and a mix of three normal bone marrow samples was used as calibrators.
For statistical analysis, the Kruskal-Wallis (KS) test was used to compare mRNA levels between different sample categories, and the Mann-Whitney (MW) test was employed to compare the expression levels between two sample groups.
AML1-ETO quantitative PCR
The expression of this abnormal transcript was investigated through the evolution of the disease by means of real-time 0 -GAAGCCAGGATCTTTATGCAC-3 0 and R: 5 0 -GAT-GGAAGCAAGAAACCAGG-3 0 ). Genomic sequences of the AML1 and CEBP-a genes were investigated by means of nonradioactive SSCP using the primers and PCR conditions reported elsewhere. 10, 11 Samples with an abnormal migration pattern on SSCP analysis were directly sequenced using forward and reverse primers in an automated sequencer (ABIPRISM 310, Applied Biosystems).
Determination of loss of heterozygosity (LOH) and microsatellite instability (MSI)
LOH and MSI analyses were performed for 14 AML1-ETO cases on paired samples corresponding to the diagnosis and remission, using four microsatellite markers (D2S391, D2S337, D2S2368 and D2S286). Aliquots of PCR products (1-2 ml) were mixed with loading buffer (2 ml formamide, 0.5 ml EDTA) and 0.5 ml of the internal size standard (Genescan-500). After denaturation for 4 min at 941C, the products were separated on polyacrylamide gels and analyzed by automatic fluorescence using the ABIPRISM 377 and software programs Genescan and Genotyper (Applied Biosystems, Foster City, CA, USA). For the intragenic marker D2S134, the PCR products were loaded on a 3% Metaphor gel and visualised using ethidium bromide.
Methylation-specific PCR (MSP) and unmethylationspecific PCR assay
A measure of 2 mg of genomic DNA was denatured by NaOH and modified by sodium bisulfite treatment, converting unmethylated (but not methylated) cytosines to uracil. 0 -TCACTAAAC-ATAAAAACACTCCA, were designed for the unmethylated sequence of the same promoter region. Initial denaturation at 941C for 3 min was followed by 40 cycles of a denaturation step at 941C for 30 s, an annealing step at 591C for 30 s, and an extension step of 721C for 30 s, followed by a final extension of 721C for 10 min.
Two PCR reactions were performed for each DNA sample: one specific for DNA originally methylated and another specific for DNA originally unmethylated using M and UM primers, respectively. PCR products were separated by electrophoresis on 2% agarose gels and visualized using ethidium bromide. The detection of a band of the appropiate molecular weight indicates the presence in the original sample of unmethylated alleles, methylated alleles, or both. The experiment was performed for four CpG islands (0, 1, 2 and 3). Freshly obtained placental DNA was used as positive methylated control.
Cell line cultures and treatment
Cell lines (NB4, Raji and Kasumi 1) were cultured in RPMI supplemented with 10% fetal bovine serum and used in different treatments with 5-Aza-2 0 -deoxycytidine (DAC), a DNA methyltransferase inhibitor and trichostatin A (TSA), which inhibits histone deacetylase activity.
Treatment A: NB4 and Kasumi cells were treated with DAC 200 nM for 48 h, with drug and medium replaced 24 h after the beginning of treatment, followed by addition of TSA, to a final concentration of 300 nM from a 1 mM ethanol-dissolved stock, for a further 48 h. Treatment B: the same as A, but with 400 nM of DAC and 600 mM of TSA. Treatment C: Raji and Kasumi cells were treated with DAC 400 nM for 24 h and TSA, to a final concentration of 800 nM from a 1 mM ethanol-dissolved stock, for a further 24 h. We also treated cells with mock, DAC and TSA by using the same volumes of ethanol and/or the same amount of drugs.
Induction of AML1-ETO transcripts in the U 937 Tet A/E cell line (a generous gift of Dr DE Zhang, Scripps Research Institute, La Jolla, CA) was performed as reported elsewhere. 12 Cell viability in treated and untreated cells was assessed by trypan blue exclusion at different times following drug exposure.
Reporter gene studies
Methylated and unmethylated Meis 1 promoter constructs were linked to the luciferase reporter gene. For normalization of transfection efficiency, we used pRL-TK plasmid (Promega, Madison, USA) that expresses Renilla luciferase.
Flow cytometry
The most immature blastic population was isolated in two AML1/ETO leukemia cases using CD34 þ microbeads (Miltenyi Biotech, Bergisch, Germany).
Analysis of DNA content and BrdU incorporation was assessed in Kasumi-1 cell line after treatment with DAC and TSA following well-established protocols. 13 Leukemic immunophenotype was analyzed in fresh samples as reported elsewhere. 14 
Results
Low Meis 1 mRNA levels in AML1-ETO leukemias
In all, 139 consecutive de novo AML cases were studied using quantitative RT-PCR assays. A discrete group of cases showed markedly diminished levels of Meis 1 and Hoxa9, whereas the values obtained for Meis 2 were high (Figures 1 and 2 ). These samples corresponded to AML1-ETO leukemia cases and patients with a normal karyotype, but with an associated in-frame CEBPa mutation in the bZIP domain (n ¼ 4, Table 1 ). These findings suggested that Hoxa9 and Meis 1 were specifically downregulated in AML1-ETO leukemias. To assess the potential inactivation of the Meis 1 gene by point mutations, a complete mutational analysis of the entire coding sequence was performed by SSCP analysis. Not a single case was identified with sequence changes and only polymorphic variations were identified (Supplemental Figure 1) . Intragenic and extragenic polymorphic markers located in the short arm of chromosome 2 were also employed to rule out the possible LOH (Supplemental Figure 2) .
Meis 1 promoter is methylated in AML1-ETO leukemias
In sharp contrast with the mutational analysis, 5 0 upstream regulatory sequences of the Meis 1 gene containing CpG islands were methylated in 9/14 cases of AML1-ETO leukemias, which correlates with their low basal expression levels. Methylation Meis 1 mRNA levels are extremely low in AML1-ETO and CEBPa mutated leukemias. Top: Amplification plot of Meis 1 in a series of AML cases where the X-axis shows the amplification cycle, and the Y-axis the normalized reporter signal minus the background noise determined during PCR cycles (DRn). Two amplification ranges can be observed: AML1-ETO patients presented Ct between 31 and 37, whereas other leukemia cases had Ct values between 18 and 22 which corresponded to high mRNA levels of Meis 1. Bottom: Expression of Meis 1 in 139 consecutive de novo AML patients represented in different colors according to their underlying molecular lesions: 18 CBFb-MYH11 (red), 19 AML1-ETO (brown), six mutated CEBPa (blue), four mutated AML1 (orange) and other 92 leukemia cases (green). From the six CEBPa cases, four had an in-frame mutation in the bZIP domain of the protein (Meis 1 downregulated) and, in the remaining two, the mutation was located outside the bZIP domain, disrupting the reading frame of the protein (Meis 1 upregulated) . (a) Meis 1 mRNA levels in the molecular subgroups of AML. Only two groups showed markedly diminished levels of the Meis 1 transcript: the AML1-ETO leukemia cases (represented as t(8;21)), and those patients with a normal karyotype but with an associated in-frame CEBPa mutation (deletion or insertion) in the bZIP domain (represented as CEBPa II). (b) Meis 2 mRNA is not repressed in myeloid leukemias. CEBPA refers to AML with CEBPa mutations (Table 1) . (c) Very low HoxA9 mRNA transcripts in core-binding factor AML.
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was a heterogeneous phenomenon: some cases showed no methylation, other cases revealed partial methylation in a single island, and still others disclosed a dense pattern in the four studied regions (case 13) (Figure 3 ). Promoter hypermethylation was absent in two normal DNA samples and in two AML cases with high Meis 1 mRNA levels. Sequencing reactions confirmed the findings observed in PCR assays (Figure 4 ). The percentage of immature cells measured as CD34 þ cells was the same for cases with and without promoter hypermethylation. When blastic subpopulations were isolated using CD34 microbeads in two AML1-ETO leukemia samples, we were able to detect comparable Meis 1 suppression in both fractions (CD34 þ : 0.0022, 0.0735 and CD34À: 0.1637 and 0.0122), suggesting that the promoter hypermethylation was not acquired during the differentiation process of the leukemic clone.
The methylated promoter construct showed a marked decrease in transcription activity when compared with the unmethylated version of the promoter.
Double treatment with DAC and TSA partially reverses Meis 1 suppression
The low levels of mRNA of Meis 1 observed in the AML1-ETO leukemic cell line (Kasumi 1) could not be corrected with DAC treatment (data not shown). These findings suggested that isolated demethylating treatment (DAC) was unable to reverse the Meis 1 inhibition present in Kasumi cell line. TSA treatment alone had no effect on Meis 1 levels. However, when a combined treatment with DAC and TSA was employed, a discrete rise in the amount of the mRNA of the Meis 1 gene was detected (Figure 5a, b) . 15 This double treatment (demethylating agent þ histone deacetylase inhibitor) was associated with a decrease in the cell viability without changes in the AML1-ETO copies determined by quantitative PCR (Figure 5c ), indicating that the specific leukemic transcript was not inhibited by this treatment. A marked increase in apoptotic cells and a G1 arrest were associated with DAC and TSA administration (Figure 5d ).
U 937 Tet AML1-ETO cell line was cultured both in the presence of tetracycline (no induction of AML1-ETO) and in the absence of tetracycline (induction of AML1-ETO expression). The growth curve showed a significant reduction of cell growth and a rise in the sub-G1 fraction (apoptotic cells) when AML1-ETO was expressed (data not shown). AML1-ETO transcript progressively increased with time, reaching a peak at 72 h, whereas the levels of Meis 1 remained constant (Table 2 ). In line In-frame bZIP mutation+frameshift mutation 6 174 346-347 del 6bp A66fsX106
Frameshift mutation Figure 3 CpG islands in the promoter region of Meis 1 are methylated in AML1-ETO leukemias. A total of 14 cases (12 AML1-ETO þ and two CEBPA mutated at the bZIP domain: patients 23 and 25) and Kasumi-1 cell line were investigated using four methylationspecific PCR (MSP). CpG islands 2 and 3 were methylated in most cases (eight and five cases, respectively). NS, no sample. with these results, Meis 1 promoter analysis showed no hypermethylation. Meis 1 repression was not an early phenomenon associated with AML1-ETO expression. The association of these molecular lesions in vivo (AML1-ETO þ Meis 1 inhibition) may require a more protracted action of the chimeric product or, alternatively, Meis1 inhibition may appear in coincidence with a second hit in the leukemic development.
In order to assess the dependence of Meis 1 expression of the leukemic clone, four patients were studied post-chemotherapy (minimal residual disease analysis) using AML1-ETO quantitative PCR. A progressive decline in AML1-ETO levels observed with the leukemia remission was associated with the normalization of the MEIS 1 mRNA values ( Figure 6 ).
Discussion
Promoter methylation is an increasingly recognized mechanism of transcriptional silencing in human cancer. Downregulated expression of target genes results from single transitional changes in these important regulatory sequences. It has been demonstrated that promoter methylation can be induced by viral agents 16, 17 or by the recruitment of methyl-transferase enzymatic machinery.
The mechanisms of leukemia induction by the AML1-ETO protein are linked to dominant inhibitory activity over normal AML1 and the recruitment of the histone-deacetylase protein complex with inhibitory properties on AML1-responsive genes, causing a block in the normal differentiation process. 18, 19 In normal granulocytic development, CEBPa plays a pivotal role through the inhibition of c-Jun. 20 It has been shown that AML1-ETO and CEBPa mutated leukemias have an inefficient transcriptional CEBPa activity. 21 This is in sharp contrast with AML cases harboring mutations in the runt domain of the AML1 gene in which the recruitment of the inhibitory complex has not been demonstrated. This raises the possibility of a different set of molecular responses in CBF leukemias, depending on whether or not the hystone-deacetylases are recruited to the AML1-responsive genes.
The current study suggests that Meis 1 is commonly inactivated through promoter methylation in AML1-ETO leukemias. This downregulation is also associated with low levels of the tightly related Hoxa9 gene. HOX proteins interact with non-HOX homeodomain cofactor proteins and these complexes can activate or repress a specific array of genes. Members of the TALE (three amino-acid loop extension) family of homeodomain cofactor proteins include PBX, MEIS 1 and PREP/KNOX1. Evidence from human and mouse leukemic cell models has Table 2 Meis1 is not downregulated at 72 h in the U 937 T AML1-ETO (t A/E) cell line The latency for the development of AML in these chimeras is much shorter when cotransfection with Meis 1 is employed. Furthermore, Meis 1 and Hoxa9 are upregulated by MLL dimers which bind to the CpG islands in the promoter region. 22 The availability of HOXA9/PBX/MEIS trimers would partially explain the different behaviour in terms of lineage maturation capabilities and therapeutic response of AML1-ETO (low levels of Hoxa9/Meis1) and MLL þ leukemias (high levels of Hoxa9/Meis 1).
Histone deacetylase and DNA methyltransferase inhibitors have recently been incorporated into the treatment of AML1-ETO leukemias. Their ability to reverse the inhibition of myeloid-specific genes helps to re-establish a normal differentiation program. Meis 1 normalization may be used as a surrogate marker of the therapeutic effects of these agents. 23, 24 In conclusion, epigenetic inactivation of Meis 1 may contribute to the acquisition of the full neoplastic phenotype in acute myeloid leukemias with AML1-ETO rearrangements. 25 
